Nkarta, Inc. Debt Securities, Available-for-sale, Realized Loss
Nkarta, Inc. (NKTX) reported Debt Securities, Available-for-sale, Realized Loss of $300.00 thousand for the 1-month period ending 2023-01-31, per its 10-K filed 2025-03-26.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2025-03-26
- 2023-01-31: Debt Securities, Available-for-sale, Realized Loss 1 month $300.00K.
- 2022-12-31: Debt Securities, Available-for-sale, Realized Loss 1 month $200.00K.
| Period end | Debt Securities, Available-for-sale, Realized Loss 1 month |
|---|---|
| 2023-01-31 | $300.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | $200.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |